Potential involvement of gelatinases and their inhibitors in Mannheimia haemolytica pneumonia in cattle.
Mannheimia haemolytica infection of the lower respiratory tract of cattle results in a bronchofibrinous pneumonia characterized by massive cellular influx and lung tissue remodeling and scarring. Since altered levels of gelatinases and their inhibitors have been detected in a variety of inflammatory conditions and are associated with tissue remodeling, we examined the presence of gelatinases in lesional and nonlesional lung tissue obtained from calves experimentally infected with M. haemolytica. Lesional tissue had elevated levels of progelatinase A and B and active gelatinase A and B when compared with nonlesional tissue obtained from the same lung lobe. In vitro, M. haemolytica products stimulated production of gelatinase B, but not its activation, by bovine monocytes. Alveolar macrophages showed constitutive production of gelatinase B but no change in response to M. haemolytica products. Bovine neutrophils exposed to M. haemolytica products also released gelatinase B, and there was a significant increase in the activated form of this enzyme. These effects were virtually identical when recombinant O-sialoglycoprotease was used to stimulate these cells. M. haemolytica products also enhanced the expression by bovine monocytes and alveolar macrophages of the tissue inhibitor of metalloproteinase 1. Our results provide evidence that matrix metalloproteinases are activated in lung lesions from cattle with shipping fever and that M. haemolytica virulence products induce production, release, and especially activation of gelatinase B by bovine inflammatory cells in vitro.
Starr
Amanda E
AE
Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1, Canada.
Dan
Tonima
T
Minhas
Kanwal
K
Shewen
Patricia E
PE
Coomber
Brenda L
BL
D000818:Animals; D002417:Cattle; D004790:Enzyme Induction; D004792:Enzyme Precursors / Q000378:metabolism*; D008168:Lung / Q000201:enzymology / Q000503:physiopathology; D008262:Macrophage Activation; D016676:Macrophages, Alveolar / Q000276:immunology; D008297:Male; D016978:Mannheimia haemolytica / Q000472:pathogenicity*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D012766:Pasteurellosis, Pneumonic / Q000201:enzymology / Q000503:physiopathology*; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*
D004792:Enzyme Precursors; D061965:Matrix Metalloproteinase Inhibitors; D019714:Tissue Inhibitor of Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9